JP2021534769A5 - - Google Patents
Info
- Publication number
- JP2021534769A5 JP2021534769A5 JP2021510191A JP2021510191A JP2021534769A5 JP 2021534769 A5 JP2021534769 A5 JP 2021534769A5 JP 2021510191 A JP2021510191 A JP 2021510191A JP 2021510191 A JP2021510191 A JP 2021510191A JP 2021534769 A5 JP2021534769 A5 JP 2021534769A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- polypeptide
- cell
- antigen
- substitution
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725977P | 2018-08-31 | 2018-08-31 | |
| US62/725,977 | 2018-08-31 | ||
| PCT/US2019/048921 WO2020047326A2 (en) | 2018-08-31 | 2019-08-29 | Decoy polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534769A JP2021534769A (ja) | 2021-12-16 |
| JPWO2020047326A5 JPWO2020047326A5 (https=) | 2022-09-06 |
| JP2021534769A5 true JP2021534769A5 (https=) | 2022-09-06 |
Family
ID=67997686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510191A Pending JP2021534769A (ja) | 2018-08-31 | 2019-08-29 | デコイポリペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210347848A1 (https=) |
| EP (1) | EP3843772A2 (https=) |
| JP (1) | JP2021534769A (https=) |
| MA (1) | MA53493A (https=) |
| WO (1) | WO2020047326A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121555430A (zh) | 2018-05-11 | 2026-02-24 | 比姆医疗股份有限公司 | 使用可编程碱基编辑器系统取代病原性氨基酸的方法 |
| AU2020394204A1 (en) * | 2019-11-27 | 2022-06-02 | ALX Oncology Inc. | Combination therapies for treating cancer |
| US12343377B2 (en) | 2020-06-01 | 2025-07-01 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| WO2022120286A1 (en) * | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| WO2025222106A1 (en) * | 2024-04-18 | 2025-10-23 | Aktis Oncology, Inc. | Decoy miniproteins, compositions, & methods of use |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US20030118997A1 (en) * | 2001-08-10 | 2003-06-26 | Genset, S.A. | Human cDNAs and proteins and uses thereof |
| US7074891B2 (en) * | 2003-02-07 | 2006-07-11 | Posco | Leukocyte stimulating peptides |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| MX2008012843A (es) | 2006-04-05 | 2009-01-19 | Univ Rockefeller | Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados. |
| BRPI0810561A2 (pt) * | 2007-04-23 | 2019-09-24 | Wyeth Corp | métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13. |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US20110237498A1 (en) * | 2008-12-19 | 2011-09-29 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| PL2995315T3 (pl) * | 2009-05-15 | 2024-04-22 | University Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47 |
| UA118950C2 (uk) * | 2011-04-22 | 2019-04-10 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора |
| SI2804617T1 (sl) | 2012-01-17 | 2020-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Visokoafinitetni SIRP-alfa reagenti |
| ES2914814T3 (es) | 2012-12-17 | 2022-06-16 | Pf Argentum Ip Holdings Llc | Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc |
| TWI759810B (zh) | 2014-08-08 | 2022-04-01 | 美商Ａｌｘ腫瘤技術股份有限公司 | 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途 |
| CA2994935A1 (en) * | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
| BR102016018074A2 (pt) * | 2015-08-07 | 2021-11-16 | ALX Oncology Inc. | Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica |
| WO2017027422A1 (en) * | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| MA47111A (fr) * | 2016-12-22 | 2019-10-30 | Univ Wake Forest Health Sciences | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer |
| WO2020177733A1 (zh) * | 2019-03-06 | 2020-09-10 | 江苏恒瑞医药股份有限公司 | 双功能融合蛋白及其医药用途 |
-
2019
- 2019-08-29 WO PCT/US2019/048921 patent/WO2020047326A2/en not_active Ceased
- 2019-08-29 EP EP19770221.0A patent/EP3843772A2/en not_active Withdrawn
- 2019-08-29 US US17/270,683 patent/US20210347848A1/en not_active Abandoned
- 2019-08-29 MA MA053493A patent/MA53493A/fr unknown
- 2019-08-29 JP JP2021510191A patent/JP2021534769A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534769A5 (https=) | ||
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| US12384850B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| JP2025118616A (ja) | 抗ｐｄ－１－抗ｖｅｇｆａ二重特異性抗体、その医薬組成物および使用 | |
| JP2025078629A5 (https=) | ||
| IL268836B1 (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| IL271325B1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| JP2019500892A5 (https=) | ||
| RU2018145961A (ru) | Комбинированная терапия | |
| CA2963696A1 (en) | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP2021513961A5 (https=) | ||
| JP2020530306A5 (https=) | ||
| CN115232209A (zh) | 靶向gprc5d的抗体及其用途 | |
| JPWO2021198965A5 (https=) | ||
| RU2020122822A (ru) | Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний | |
| JP2021505637A5 (https=) | ||
| US20250236864A1 (en) | CAR LIBRARY AND scFv MANUFACTURING METHOD | |
| JPWO2020047326A5 (https=) | ||
| JP2020525432A (ja) | 非対称ヘテロ二量体ＦＣ−ＳＣＦＶ融合抗ＧＬＯＢＯ Ｈおよび抗ＣＤ３二重特異的抗体およびがん療法（ｃａｎｅｒ ｔｈｅｒａｐｙ）におけるその使用 | |
| CN115298219A (zh) | 多特异性抗体在治疗数个疾病方面的用途 | |
| JPWO2023037268A5 (https=) | ||
| CA3221115A1 (en) | Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies | |
| JPWO2021016585A5 (https=) |